Metacrine, Inc. (MTCR)
Stock Price:
$8.21 USD
-0.29 (-3.41%)
Updated November 25, 4:00 PM EST - Market closed
Key Info
| Market Cap |
213.10M |
| Revenue (ttm) |
2.18M |
| Net Income (ttm) |
-33.30M |
| Shares Out |
25.96M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 25 |
| Last Price |
$8.21 |
| Previous Close |
$8.50 |
| Change ($) |
-0.29 |
| Change (%) |
-3.41% |
| Day's Open |
8.24 |
| Day's Range |
8.07 - 8.44 |
| Day's Volume |
65,793 |
| 52-Week Range |
8.05 - 16.19 |
More Stats
| Market Cap |
213.10M |
| Enterprise Value |
115.09M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.96M |
| Float |
8.41M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
94,930 |
| Short Ratio |
0.87 |
| Short % of Float |
1.13% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
97.98 |
| PB Ratio |
2.58 |
| Revenue |
2.18M |
| Operating Income |
n/a |
| Net Income |
-33.30M |
| Free Cash Flow |
n/a |
| Net Cash |
98.01M |
| Net Cash / Share |
3.78 |
| Gross Margin |
-1,194.16% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.50*
(149.70% upside)
Low
18.0
Current: $8.21
High
25.0
Target: 20.50
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | 1.45 |
| Gross Profit | - | 1.45 |
| Operating Income | -30.00 | -26.73 |
| Net Income | -28.93 | -25.82 |
| Shares Outstanding | 2.38 | 2.09 |
| Earnings Per Share | -12.17 | -12.35 |
| Operating Cash Flow | -27.75 | -25.48 |
| Capital Expenditures | -0.08 | -0.68 |
| Free Cash Flow | -27.83 | -26.16 |
| Cash & Equivalents | 55.65 | 72.99 |
| Total Debt | 11.45 | 2.85 |
| Net Cash / Debt | 44.20 | 70.13 |
| Assets | 60.28 | 77.80 |
| Liabilities | 139 | 129 |
| Book Value | -78.24 | -51.47 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Metacrine, Inc. |
| Country |
United States |
| Employees |
32 |
| CEO |
Preston S. Klassen |
Stock Information
| Ticker Symbol |
MTCR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MTCR |
| IPO Date |
September 16, 2020 |
Description
Metacrine, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases in the United States. It is developing MET409, a therapy that is in a Phase Ib proof-of-concept clinical trial for the treatment of non-alcoholic steatohepatitis patients; and MET642, a candidate, which is in Phase 1 clinical trial for the treatment of non-alcoholic steatohepatitis patients. The company has a research collaboration with Novo Nordisk A/S to perform research activities related to fibroblast growth factor 1. Metacrine, Inc. was founded in 2014 and is headquartered in San Diego, California.